No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 35 of the 40 quarters in the window, leaving 5 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 142.9x · 10Y median 445.7x · 8th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:52:19.718Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Microbot Medical Inc. (MBOT) stock was $1.09 as of Oct 6, 2026, 1:49 PM EDT, up 1.40% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -65.0% · 3-year avg -7.7%/yr · 5-year avg -31.6%/yr
Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures.
Medical - Devices · Hingham, MA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.08
Revenue Est.
$-72000.00
Last Quarter Results
EPS
$-0.08
vs Estimate
$-0.08
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MBOT | $49.44M | $1.08 | +1.40% | -64.98% | -31.63% | -39.57% | N/A |
| 2INMB | $49.45M | $1.86 | -4.12% | -6.70% | -36.88% | N/A | vs MBOT |
| 3SRTS | $49.55M | $3.01 | +3.08% | -14.80% | -4.37% | -7.40% | vs MBOT |
| 4TELA | $49.21M | $1.10 | -3.51% | -26.81% | -38.71% | N/A | vs MBOT |
| 5APLM | $49.72M | $22.64 | -2.69% | +26.12% | N/A | N/A | vs MBOT |
| 6ELOX | $50.51M | $14.70 | -4.61% | N/A | N/A | N/A | vs MBOT |
forward FY estimate
N/A
$200000.00
vs Estimate
$133333.00
Consensus Rating
Based on 3 analysts
Average Price Target
$6.33
+483.7% upside
Low
$3.00
Current
$1.08
High
$12.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.11 | $-0.08 | $-0.05 | 2 |
| Quarter ending Dec 2026 | $-0.12 | $-0.08 | $-0.06 | 2 |
| Quarter ending Mar 2027 | $-0.13 | $-0.09 | $-0.06 | 1 |
| Quarter ending Jun 2027 | $-0.13 | $-0.09 | $-0.06 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.29 | $-0.26 | $-0.22 | 2 |
| FY 2027 | $-0.31 | $-0.30 | $-0.29 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $187499.00 | $250000.00 | $328123.00 | 2 |
| Quarter ending Dec 2026 | $270248.00 | $360333.00 | $472935.00 | 2 |
| Quarter ending Mar 2027 | $649998.00 | $866667.00 | $1.14M | 1 |
| Quarter ending Jun 2027 | $874997.00 | $1.17M | $1.53M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $139443.00 | $174667.00 | $210624.00 | 2 |
| FY 2027 | $3.42M | $5.09M | $6.77M | 2 |
